180 related articles for article (PubMed ID: 3055921)
1. Efficacy and long-term adverse effect pattern of lovastatin.
Tobert JA
Am J Cardiol; 1988 Nov; 62(15):28J-34J. PubMed ID: 3055921
[TBL] [Abstract][Full Text] [Related]
2. HMG CoA reductase inhibitors. Current clinical experience.
Walker JF
Drugs; 1988; 36 Suppl 3():83-6. PubMed ID: 3076126
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with lovastatin.
Tobert JA; Shear CL; Chremos AN; Mantell GE
Am J Cardiol; 1990 Mar; 65(12):23F-26F. PubMed ID: 2180268
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
5. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up.
Bradford RH; Shear CL; Chremos AN; Dujovne CA; Franklin FA; Grillo RB; Higgins J; Langendorfer A; Nash DT; Pool JL
Am J Cardiol; 1994 Oct; 74(7):667-73. PubMed ID: 7942524
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical tolerance of lovastatin and simvastatin.
Bilheimer DW
Cardiology; 1990; 77 Suppl 4():58-65. PubMed ID: 2073673
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of lovastatin in 3390 women with moderate hypercholesterolemia.
Bradford RH; Downton M; Chremos AN; Langendörfer A; Stinnett S; Nash DT; Mantell G; Shear CL
Ann Intern Med; 1993 Jun; 118(11):850-5. PubMed ID: 8480959
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV.
Arch Intern Med; 1993 May; 153(9):1079-87. PubMed ID: 8481075
[TBL] [Abstract][Full Text] [Related]
9. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
[TBL] [Abstract][Full Text] [Related]
10. Extended clinical safety profile of lovastatin.
Mantell G; Burke MT; Staggers J
Am J Cardiol; 1990 Sep; 66(8):11B-15B. PubMed ID: 2206031
[TBL] [Abstract][Full Text] [Related]
11. Simvastatin in severe primary hypercholesterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The Principal Investigators.
Simons LA
Clin Cardiol; 1993 Apr; 16(4):317-22. PubMed ID: 8458112
[TBL] [Abstract][Full Text] [Related]
12. Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin.
Dujovne CA; Chremos AN; Pool JL; Schnaper H; Bradford RH; Shear CL; Higgins J; Downton M; Franklin FA; Nash DT
Am J Med; 1991 Jul; 91(1B):25S-30S. PubMed ID: 1831006
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Yee HS; Fong NT
Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
15. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. The Lovastatin Study Group III.
JAMA; 1988 Jul; 260(3):359-66. PubMed ID: 2898027
[TBL] [Abstract][Full Text] [Related]
16. Lovastatin: a new cholesterol-lowering agent.
McKenney JM
Clin Pharm; 1988 Jan; 7(1):21-36. PubMed ID: 3278832
[TBL] [Abstract][Full Text] [Related]
17. HMG CoA reductase inhibitors as lipid-lowering agents: five years experience with lovastatin and an appraisal of simvastatin and pravastatin.
Maher VM; Thompson GR
Q J Med; 1990 Feb; 74(274):165-75. PubMed ID: 2111917
[TBL] [Abstract][Full Text] [Related]
18. Safety of statins: effects on muscle and the liver.
Vasudevan AR; Hamirani YS; Jones PH
Cleve Clin J Med; 2005 Nov; 72(11):990-3, 996-1001. PubMed ID: 16315438
[TBL] [Abstract][Full Text] [Related]
19. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Pedersen TR; Tobert JA
Drug Saf; 1996 Jan; 14(1):11-24. PubMed ID: 8713485
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic use of lovastatin in the treatment of hypercholesterolemia.
Illingworth DR
Clin Ther; 1994; 16(1):2-26; discussion 1. PubMed ID: 8205598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
